One Year Later: Medical Abortion After FDA Approval-3170
One Year Later: Medical Abortion After FDA Approval
On September 28, 2000, the Food and Drug Administration (FDA) approved mifepristone (RU486), the first dedicated medical abortion pill regimen. Many advocates on both sides of the abortion debate predicted that arrival of this new option would transform the abortion landscape – for women, for doctors, and for politicians. So, a year later, where are we?
To help shed light on this issue, the Kaiser Family Foundation conducted a survey of women's health providers about their provision of and attitudes towards mifepristone. The survey findings and the additional resource material below were developed as part of the Foundation's ongoing media briefing series, Emerging Issues in Reproductive Health. (A corresponding event, originally scheduled for September 20 in New York City, was cancelled due to the tragic events of September 11, 2001.)
- News Release: Few Offering Mifepristone One Year After FDA Approval; Indications That Numbers May Increase in Next Year
- Chart Pack
- Toplines/Survey: National Survey of Women's Health Care Providers on Reproductive Health: Medical Abortion Results
- Resource List
- Fact Sheet: Abortion in the U.S.
- Issue Update: Mifepristone: An Early Abortion Option
- Issue Update: Abortion Policy and Politics
also of interest
- Updating the Ryan White HIV/AIDS Program For A New Era: Key Issues and Questions for the Future
- Financing the Response to AIDS in Low- and Middle-Income Countries: International Assistance from Donor Governments in 2012
- The Single Streamlined Application Under the Affordable Care Act: Key Elements of the Proposed Application and Current Medicaid and CHIP Applications